- Supported exchanges /
- LSE /
- 0QIU.LSE
Novo Nordisk A/S Class B (0QIU LSE) stock market data APIs
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S Class B Financial Data Overview
| 919.15 | |
| 919.15 | |
| - | |
| 932.65 | |
| 918.7 | |
| 607.5926-1028.207 | |
| 19 895 M | |
| 0.3896 | |
| 2 414 M | |
| 201 325 M | |
| 4.4901 | |
| 0.0169 | |
| 0.2421 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Novo Nordisk A/S Class B Fundamental Data is available in our Financial Data APIs
- Net Revenue 201 325 M
- EBITDA 92 893 M
- Earnings Per Share 21.502
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Novo Nordisk A/S Class B Earnings via APIs
- Latest Release 2024-08-07
- EPS/Forecast NaN
Get Novo Nordisk A/S Class B End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
